[Dabrafenib plus trametinib for advanced melanoma]
Gonzalez L, Oubiña M, Sebastián García Martí, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A
Record ID 32018001290
Spanish
Original Title:
Dabrafenib, trametinib y cobimetinib para el tratamiento del melanoma
Authors' recommendations:
CONCLUSIONS High quality evidence shows that the use of dabrafenib plus trametinib in patients with irresecable or metastatic melanoma with BRAF V600 mutation is associated to a longer overall survival, progression-free survival and a better overall response rate when compared with dabrafenib or vemurafenib as monotherapies. No studies comparing this combination with other treatment options currently considered as first line such ipilimumab, anti-PD1 antibodies have been found, although there is evidence from indirect comparisons that suggests there would be no differences in overall survival versus nivolumab, pembrolizumab antibodies or the vemurafenib/cobimetinib combination.
The clinical practice guidelines from the main oncology societies consider the combination among the treatment options for the mentioned population; its use as first line is preferred in case of need for a rapid clinical response based on symptoms and/or disease tumor burden. Also several public and private health sponsors consulted consider the use of both drugs in combination in patients with advanced melanoma.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Melanoma
- Antineoplastic Combined Chemotherapy Protocols
- Skin Neoplasms
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Adjuvants, Immunologic
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.